Headquarters
Japan
Every company in the roster headquartered in Japan.
Research
Compare company financial metrics
Research adds sourced market cap, cash, runway and annualized R&D figures with metric-specific sorting.
Views
14 of 14 companies
| Company | Pipeline | Most advanced | Next readout |
|---|---|---|---|
 Takeda Pharmaceutical CompanyTAK · NYSE | 18 assets: 8 approved, 9 Ph 3, 1 Ph 2 | zasocitinibPhase 3 · Psoriatic ArthritisReliable signal | 17 Feb 2027zasocitinib · Phase 2 |
 Daiichi Sankyo4568 · TSE | 12 assets: 3 approved, 5 Ph 3, 3 Ph 2, 1 Ph 1 | MirogabalinPhase 3 · Diabetic Peripheral Neuropathic PainReliable signal | 20 Oct 2026DS-3939a · Phase 1/2 |
 Otsuka Holdings4578 · TSE | 12 assets: 8 approved, 2 Ph 3, 1 Ph 2, 1 Ph 1 | OPC-61815Phase 3 · Heart FailurePartial signal | 20 Oct 2026Ulotaront · Phase 3 |
 Eisai4523 · TSE | 9 assets: 5 approved, 3 Ph 3, 1 Ph 2 | LemborexantPhase 3 · Alzheimer's DiseasePartial signal | 3 Dec 2026Lecanemab · Phase 2 |
 Astellas Pharma4503 · TSE | 7 assets: 2 approved, 4 Ph 3, 1 Ph 1 | RoxadustatPhase 3 · Chronic Kidney DiseaseReliable signal | 31 Oct 2026Setidegrasib · Phase 1 |
 Kyowa Kirin4151 · TSE | 6 assets: 2 approved, 1 Ph 3, 3 Ph 1 | RTA 402Phase 3 · Type 2 DiabetesReliable signal | Dec 2027KK3910 · Phase 1 |
 Mitsubishi Tanabe PharmaPrivate | 5 assets: 4 Ph 3, 1 Ph 2 | MP-513Phase 3 · Type 2 DiabetesReliable signal | None on record |
 Ono Pharmaceutical4528 · TSE | 5 assets: 3 Ph 2, 2 Ph 1 | ONO-1110Phase 2 · Major Depressive DisorderPartial signal | 31 Dec 2026ONO-2020 · Phase 2 |
 Kissei Pharmaceutical4547 · TSE | 4 assets: 2 Ph 3, 2 Ph 2 | JR-131Phase 3 · Chronic Kidney DiseasePartial signal | None on record |
 Sanwa Kagaku KenkyushoPrivate | 2 assets: 1 approved, 1 Ph 3 | UpacicalcetPhase 3 · Chronic Kidney DiseasePartial signal | None on record |
 Shionogi4507 · TSE | 2 assets: 2 Ph 3 | PravafenixPhase 3 · Atherosclerotic Cardiovascular DiseasePartial signal | None on record |
 FUJIFILM Toyama ChemicalPrivate | 1 asset: 1 Ph 3 | IguratimodPhase 3 · Rheumatoid Arthritis | None on record |
 Heartseed219A · TSE | 1 asset: 1 Ph 2 | HS-001Phase 1/2 · Heart Failure | None on record |
 Rohto Pharmaceutical4527 · TSE | 1 asset: 1 Ph 2 | ADR-002KPhase 2 · Heart Failure | 30 Sep 2028ADR-002K · Phase 2 |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov).